
ç¯çœªçæ æ ¢ïŒCDCã¯COVIDã¯ã¯ãã³ãè¥ãç·æ§ã«å¿ççãåŒãèµ·ããå¯èœæ§ãããããšããäžè¬ã«å ¬è¡šããæ°ã«æåã«ç¥ã£ãŠããã
å èšäºã¯ãã¡ã/Original article here
COVID-19ã¯ã¯ãã³ãç±³åœã§äžè¬ã«é åžãããŠãã2ãµæåŸã8æ³ãã21æ³ã®ç·æ§ã«ãããå¿ççã«ã€ããŠãçµ±èšçã«ææãªã¯ã¯ãã³å®å šæ§ã·ã°ãã«ãçŸç 察çã»ã³ã¿ãŒïŒCDCïŒã®ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã«çŸããŸãã-ãããCDCåœå±ã¯ãäžè¬åžæ°ã«èŠåããåã«ããã«3ãµæåŸ ã¡ãŸããããšæ°ããç ç©¶ã¯è¿°ã¹ãŠããŸãã
ãã®ç ç©¶ã¯ãDelayed Vigilance: Karl Jablonowski, Ph.D., and Brian Hooker, Ph.D., P.E.ã«ããç ç©¶ ãA Comment on Myocarditis in Association with the COVID-19 Injectionsã ã¯ã10æ17æ¥ã« International Journal of Vaccine Theory, Practice, and Research ã«çºè¡šãããŸããã
The Defenderã®ã€ã³ã¿ãã¥ãŒã§ãChildren's Health Defenseã®æé«ç§åŠè²¬ä»»è ã§ããHookeræ°ã¯æ¬¡ã®ããã«èªã£ãŠããŸãã
ããã®éèŠãªè«æã¯ã8æ³ãã21æ³ã®ç·æ§ã«ãããå¿ççã«é¢ãã匷åã§çµ±èšçã«ææãªã¯ã¯ãã³æå®³äºè±¡ãã·ã°ãã«ãããCOVID-19ã¯ã¯ãã³ãç±³åœåœæ°ã«ãªãªãŒã¹ãããŠããããã2ã¶æåŸã®2021幎2æ19æ¥ã®æç¹ã§VAERSããŒã¿ããŒã¹äžã«ç¢ºèªãããããšã瀺ããŠããŸããã
ãCDCè·å¡ã¯ãã®ã·ã°ãã«ã«é¢ããŠèŠéã鳎ãã代ããã«ã2021幎5æ27æ¥ãŸã§COVID-19ã¯ã¯ãã³æ¥çš®ãšå¿ççã®é¢é£æ§ãè¬ãå»ããŸããããã®æ¥ãŸã§ã«ã察象ãšãªãç±³åœäººå£ã®50%以äžããå°ãªããšã1åã®mRNA COVID-19ã¯ã¯ãã³ãåããŠããŸãããã
ããã®çš®ã®æ å ±ã®é èœã¯ç¯çœªçã§ãã
åœç«çšå°çŸæ£ç ç©¶æ©æ§ã®ç ç©¶è ã«ãããšãå¿ççã¯ãææçããçããããšãããã°ãæ¯çŽ ããŠã€ã«ã¹ãªã©ã®æ¯æ§äœçšããçŽæ¥çããããšããããšã®ããšã§ãããããäžè¬çã«ã¯ãå¿ççã¯ãæåã®å¿èã®æå·ã«å¯Ÿããäœã®å ç«åå¿ã®çµæã§ããããšç ç©¶è ã¯è¿°ã¹ãŠããã
é床ã®å¿ççã¯ãå¿çã«æ°žä¹ çãªæå·ãäžããå¿äžå šãåŒãèµ·ããå¯èœæ§ããããŸãã
Jablonowskiæ°ãšHookeræ°ã¯ãç±³åœã§ã¯ã¯ãã³ã®å¯åå¿ãå ±åããæ¿åºåºè³ã®äž»èŠã·ã¹ãã ã§ããVAERSã«ãããŠãå¿ççãåŸã ã«çµ±èšçã«ææãªãã·ã°ãã«ããšãªãããã®çºççã®å¢å ãèšé²ã»åæããã
ãããïŒå¿ççïŒã¯æéãšãšãã«å®³ã®èå¥å¯èœãªææšãšãªããããã§ã¯2021幎2æ19æ¥ã®é±ã«çµ±èšçã«ææãšãªã£ãææã瀺ããŠããŸã ããšèè ãã¯èª¬æããŠããŸãã
ããããããã2ã«æåŸã®2021幎4æ23æ¥ã®é±ã®VAERSããŒã¿ã§ã¯ãCOVID-19æ¥çš®åŸã®è¥ãç·æ§ã«ãããå¿ççã®èå¥å¯èœãªã¬ãã«ããæ¥µç«¯ãªçµ±èšçã¬ãã«ã«ãŸã§äžæããããšã瀺ãããŠããŸãã
äžè¬ã«ãpå€ã0.05æªæºã§ããã°çµ±èšçã«ææã§ãããšèŠãªããã芳å¯ãããçµæãå¶ç¶ã«èµ·å ããããšã¯åççã§ã¯ãªãããšãæå³ããpå€ã0.01æªæºã§ããã°éåžžã«çµ±èšçã«ææã§ãããšèŠãªãããŸãã
2021幎4æ23æ¥ã®é±ãŸã§ã«ãJablonowskiãšHookerã¯ã0.0001æªæºã®på€ïŒp<0.0001ïŒã確èªããŸããã
ããã®pã¬ãã«ã§ã¯ãVAERSããŒã¿ã§èгå¯ããããããªå€§ããªã³ã³ãã©ã¹ãã¯ã1äžä»¶ã®åæ§ã®å®éšè¬è©Šéšã§1åæªæºããçºçããªããšäºæ³ãããŸããããšåœŒãã¯è¿°ã¹ãŠããŸãã
ããã®çµ±èšå€ã¯ãç±³åœäººå£ã®43.78%ãå°ãªããšã1åã®[COVID-19]泚å°ãåããŠããæã«åŸããããã®ã§ã31.20%ã¯ãå©çšå¯èœãŸãã¯æŒãä»ãããããããã®æ³šå°ã®å šãŠãåãã12.58%ãCOVID-19泚å°ã®äžã€ä»¥äžãåãããå šãŠãåããŠã¯ããªãã£ããããšè¿°ã¹ãŠããŸãã
ãã®å®å šæ§ã®ã·ã°ãã«ã«ããããããã2021幎5æ10æ¥ãç±³åœé£åå»è¬åå±ã¯ããã¡ã€ã¶ãŒã»ãã€ãªããã¯ç€Ÿã®COVID-19ã¯ã¯ãã³ã®ç·æ¥äœ¿çšèš±å¯ã12æ³ã®äººã«ãæ¡å€§ããCDCã®äºé²æ¥çš®å®æœè«®åå§å¡äŒã¯ã12æ³ä»¥äžã®äººããã®ã¯ã¯ãã³ãåããããšããã¹ãŠæšå¥šããããšã決è°ããã
åãé ãCDCã®V-safeãšããã¯ã¯ãã³æ¥çš®åŸã®ããŒã¿åéããŒã«ã§ã12æ³ãã15æ³ã®éå°å¹Žããã®èšå ¥ãåãä»ããããã«ãªã£ããæ°é±éåŸãCDCã¯ã€ãã«mRNA COVID-19ã¯ã¯ãã³æ¥çš®ãšå¿ççã«é¢é£ãããå¯èœæ§ãå ¬ã«èªããŸããã
2021幎5æ27æ¥ãCDCã¯ãŠã§ããµã€ãäžã§ãmRNA COVID-19ã¯ã¯ãã³æ¥çš®åŸã®å¿ççãšå¿èçãïŒãã®èšäºã®å·çæç¹ã§ã¯ããçºè¡šãããŠããªãããã ããDasãã2021幎åç §ïŒãçºè¡šããŸããã
ãããããããã§åŒ·èª¿ãããéèŠãªç¹ã¯ãäžè¬å€§è¡ããç±³åœäººå£ã®50.56ïŒ ããæ¢ã«1å以äžãå©çšã§ããå šãŠã®COVID-19泚å°ã®éçãŸã§åããåŸ-42.25ïŒ ãäžé£ã®æ³šå°ãå®å šã«åãã8.31ïŒ ãäžéšãåãããå šãŠåããŠããªã-æç¹ã§ãå¿ççã®ç¹å®ã®çåœã«é¢ããå±éºæ§ã«æ°ã¥ãããã«ãªã£ããããããšã§ãããšè¿°ã¹ãŠããŸãã
ããªãåãè¿ãã®ã€ããªãèŠæã®é ããçããã®ãããšåœŒãã¯åããããã
CDCã¯ããæå³çã«ãããå±éããã蚌æ ãç¡èŠããã«ãããã2021幎5æ27æ¥ãŸã§ããç±³åœäººå£ã®50.56ïŒ ããã§ã«æ³šå°ãåãããã®ãã¡ã®ããã€ãã¯è€æ°ååããŠããã®ã«ããmRNAã®COVID-19ã«ãã被害ãåºããå¯èœæ§ã«ã€ããŠç±³åœåžæ°ã«èŠåããªããšããéžæãããããšã¯ããç¯çœªçç¡èŠããšç¹åŸŽã¥ãããããããããªãã
JablonowskiãšHookerã¯ããçµè«ã¥ããã
ã2021幎2æ19æ¥ãããç±³åœäººå£ã®ããã14.23ïŒ ãå°ãªããšã1åã®æ³šå°ãåããåŸãVAERSããŒã¿ã®ã·ã°ãã«ã¯ãã§ã«ã¯ã£ãããšãããã®ã«ãªã£ãŠããã5æ27æ¥ãŸã§ã«æ³šå°ã«äŒŽããªã¹ã¯ãè² ã£ã50.56%ãããã®ã°ã«ãŒããå·®ãåŒããšãç±³åœäººå£ã®36.33%(ããã1å2000äžäºº)ããã³ãã19泚å°ã«äŒŽãå¿ççã®äžå¯éçæå·ãå«ãæ¢ç¥ã®æå®³äºè±¡ã«ã€ããŠç¥ããããŠããªãç¶æ ã§ãã£ããã
VAERSã®ããŒã¿ã«ãããšã2020幎12æ14æ¥ãã2022幎10æ14æ¥ã®éã«å¿ççããã³å¿èçã24,371ä»¶å ±åãããŠããŸãããã®ãã¡ã1,333ä»¶ã®å ±åã¯12æ³ãã17æ³ã47ä»¶ã®å ±åã¯5æ³ãã11æ³ã5ä»¶ã®å ±åã¯çåŸ6ã«æãã5æ³ã®éã§çºçããã
CDCã§ã¯ãå¿åæ¢ãèè¡æ§è³åäžãææ¥å€æ¥ãå蚺ããåã«å¿èã®åé¡ã§æ»äº¡ããã±ãŒã¹ãé€å€ããŠãç矩ã®ãå¿ççããå®çŸ©ããŠããŸãã
VAERSã«æåºãããå ±åã¯ãå æé¢ä¿ã確èªããããã«ãããªã調æ»ãå¿ èŠã§ããããã®ã·ã¹ãã ã§ã¯å®éã®ã¯ã¯ãã³æå®³äºè±¡ã®1ïŒ ããå ±åãããŠããªãããšãåãã£ãŠããŸãã